Investors with Losses in Excess of $100,000 in ADMP Stock: Investigation of Adamis Pharmaceuticals Corporation Announced by The Law Offices of Howard G. Smith

Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of Adamis Pharmaceuticals Corporation ("Adamis" or the "Company") (Nasdaq: ADMP) concerning possible violations of federal securities laws. The investigation concerns whether Adamis and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

Investors who have lost in excess of $100,000 in Adamis stock are encouraged to contact Howard G. Smith at 215-638-4847, toll-free at 888-638-4847, or by email to howardsmith@howardsmithlaw.com. If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

On March 27, 2015, Adamis issued a press release announcing that it had received a Complete Response Letter ("CRL") from the U.S. Food & Drug Administration ("FDA") regarding the Company's New Drug Application ("NDA") for its Epinephrine Injection USP 1:1000 0.3mg Pre-filled Single Dose Syringe, or the Epinephrine PFS product, for the emergency treatment of acute anaphylaxis, which is a severe allergic reaction. According to the Company, "on May 28, 2014, we submitted an NDA to the FDA pursuant to Section 505(b)(2) of the Food, Drug & Cosmetic Act, as amended, for approval of the Epinephrine PFS product. The Epinephrine PFS delivers a premeasured dose of ephinephrine for the emergency treatment of anaphylaxis. A CRL is issued by the FDA's Center for Drug Evaluation and Research when it has completed its review of a file and questions remain that preclude the approval of the NDA in its current form. The questions raised by the FDA in the CRL pertained to Chemistry, Manufacturing and Controls ("CMC") relating to the volume of dose delivered by the syringe, including the ability to deliver volume within the levels contained in the labeling claim and as required by the FDA."

After the release of this news, shares of Adamis fell $1.41 per share to $3.98, or more than 26.16%, in intra-day trading on March 30, 2015.

If you purchased shares of Adamis, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at 215-638-4847, toll-free at 888-638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at http://www.howardsmithlaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.